Avadel and nference announce publication of real-world data on sodium oxybate treatment patterns in the journal of clinical neuroscience

-- retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate -- -- one third of patients taking immediate-release, twice-nightly sodium oxybate discontinued treatment, most often due to lack of efficacy; inability to wake up was most common reason for missing second nightly dose -- dublin, april 17, 2025 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a biopharmaceutical company focused on transforming medicines to transform lives, and  nference , a health tech company dedicated to making biomedical data computable, today announced the publication of real-world data on comorbidities and treatment patterns of people with narcolepsy treated versus not treated with immediate-release sodium oxybate.
AVDL Ratings Summary
AVDL Quant Ranking